Trial · NCT05996627
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
NCT05996627, Phase 2, Recruiting, Fred Hutchinson Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease. Trials, record NCT05996627. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05996627
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
- NCT number
- NCT05996627
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 82 participants, estimated
- Lead sponsor
- Fred Hutchinson Cancer Center
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil, Biospecimen Collection, Electronic Health Record Review, Placebo Administration
- First posted
- 2023-08-18
- Last updated
- 2026-09-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to start of subsequent systemic immune suppressive treatment for chronic graft versus host disease (cGVHD) | From first dose of study medication to starting a new systemic immunosuppressive agent for cGVHD therapy, up to 12 months | Systemic therapies include any systemic agent given for a cGVHD indication, including extracorporeal photopheresis. Will use Gray's test. Point estimates of new systemic immunosuppressive use will be obtained using cumulative incidence estimates. |
| Secondary | Event-free survival | From randomization to death, malignancy relapse or addition of a new systemic immune suppressive therapy, up to 12 months or end of study | Point estimates will be obtained using the method of Kaplan and Meier and the log-rank test will be used to assess the difference between treatment groups. |
| Secondary | Overall survival | Up to 12 months or end of study | Point estimates will be obtained using the method of Kaplan and Meier and the log-rank test will be used to assess the difference between treatment groups. |
| Secondary | Rate of relapse | Up to 12 months or end of study | Point estimates will be obtained using the method of Kaplan and Meier and the log-rank test will be used to assess the difference between treatment groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05996627
GET https://conductscience.org/api/trials/v1/NCT05996627/registered